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Abstract
L-Glutamine (GLN) is considered a nonessential amino acid that has a variety of 
applications in naturopathic medicine. It has been postulated that in the critically ill 
patient, GLN becomes an essential amino acid for recovery, restoration, and repair at a 
cellular level. Mucositis is an intestinal mucosal damage of the gastrointestinal tract—
mouth, throat, stomach, intestines, rectum, and anus—that is caused directly by 
chemotherapies and radiotherapies. Cancer cachexia is a significant biochemical event, 
which is characterized by weight loss, fatigue, and indicative of depletion of skeletal 
muscle GLN—a hypercatabolic state. There has been some question as to the use of 
GLN in this patient population because of its role as a preferred energy source not only 
for enterocytes and lymphocytes but for malignant cells as well. This article will address 
the questions of safety, efficacy, dosing, and toxicity of GLN used as an integrative 
therapeutic in ongoing naturopathic integrative cancer treatment.
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Conclusion
Biochemical analysis, in vitro and in vivo, animal 
and human studies along with phase I-phase II 
human clinical trials with pilot phase III clinical trials 
have shown that oral GLN is a safe and effective 
strategy to prevent and treat mucositis, stomatitis 
and cachexia. Concerns are that  GLN will 
preferentially be used by the cancer cells, giving a 
tumor protective effect. Results show that GLN is 
not taken up by the cancer but preferentially by the 
healthy non cancer tissues like muscles, gut 
mucosa, and lymphocytes. It has been shown that 
cancer growth is not only reduced by GLN but also 
counterbalanced by support of the lost GLN stores 
and GLN production in healthy cells. Immune 
function was also increased via the increased 
activity of NK cells by the suppression
of the PGE2 series. Thus, GLN not only has a
preventive effect against mucositis and cachexia 
but a therapeutic effect against cancer cells in 
relation to the host’s defenses and ability to tolerate 
chemotherapy. GLN has gained acceptance as an 
essential amino acid, it not only modulates the 
immune system’s function at the gut level but also 
promotes faster intestinal healing, significantly 
decreasing the severity of mucositis/stomatitis 
induced by chemotherapy and radiation therapy. 
Dosing and Toxicity
GLN may also enhance the selectivity
of antitumor drugs by sensitizing the tumor 
cells to the oncological therapeutics while 
protecting normal cells in healthy tissues. 
This ability to evade chemoresistance is a 
very important finding to add to the 
strategies of integrative oncology.
Dosing ranges may vary depending on the 
status of the individual patients’ liver 
enzymes because GLN can transiently raise 
the levels of AST and ALT. Although there 
are no current data that contraindicate the 
use of GLN with elevated liver 
transaminases, the current clinical thinking 
is that if the AST/ALT levels are higher than 
3 times the normal ranges, GLN should be 
used as a swish and spit, and not as a 
swish and swallow. Safe dosing strategies 
include continued monitoring of these 
enzyme levels for this possible effect of 
GLN supplementation. For effective and 
safe dosing strategies range from 10grams 
usually 3 times per day, swished and
swallowed for optimum  local contact of 
GLN with the mucous membranes.
